Compare Pinterest Inc (PINS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pinterest Inc vs Summit Therapeutics Inc — how do they compare? Pinterest Inc trades at $21.31 (market cap $11.63B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Pinterest Inc is more actively traded (12,792,940 versus 6,173,057). Which is the better fit depends on your goals — on Pluang, investors hold Pinterest Inc for 85 Days and Summit Therapeutics Inc for 16 Days on average.
| PINS | SMMT | |
|---|---|---|
Market Cap | $11.63B | $13.71B |
Volume | 12,792,940 | 6,173,057 |
Sector | Media | Health |
52-Week High | $35.24 | $26.38 |
52-Week Low | $15.42 | $12.43 |
Typical Hold Time | 85 Days | 16 Days |
Enterprise Value | $11.55B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pinterest (PINS) trades at $21.40, up 5.37% with bullish technical signals despite mixed oscillators. The company shows strong revenue growth from $2.8B in 2022 to $4.2B in 2025, with recent earnings beats and a 79.5% gross margin. Analyst consensus is bullish with a $27.93 price target, though high P/E of 60.4 and insider selling pose valuation concerns.
Outlook remains positive driven by international monetization and new ad products, but risks include competitive pressure and reliance on advertising revenue. The stock offers growth potential if execution continues, though current valuation demands careful monitoring of earnings sustainability.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
